You are now leaving www.admabiologics.com
The link you have selected will take you outside of ADMA Biologics corporate website. The site you will be entering is intended for U.S. audiences only. Do you wish to continue?
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($) |
3 Months Ended | 9 Months Ended | ||
|---|---|---|---|---|
Sep. 30, 2020 |
Sep. 30, 2019 |
Sep. 30, 2020 |
Sep. 30, 2019 |
|
| REVENUES: | ||||
| Product revenue | $ 10,240,650 | $ 7,186,795 | $ 28,156,571 | $ 17,204,909 |
| License revenue | 35,708 | 35,708 | 107,125 | 107,125 |
| Total Revenues | 10,276,358 | 7,222,503 | 28,263,696 | 17,312,034 |
| OPERATING EXPENSES: | ||||
| Cost of product revenue (exclusive of amortization expense shown below) | 11,855,464 | 7,916,220 | 42,180,319 | 27,812,635 |
| Research and development | 1,708,391 | 491,404 | 4,893,549 | 1,879,025 |
| Plasma center operating expenses | 1,218,898 | 456,899 | 2,597,444 | 1,705,498 |
| Amortization of intangible assets | 178,838 | 211,235 | 536,514 | 633,704 |
| Selling, general and administrative | 9,115,744 | 7,197,173 | 25,750,458 | 18,878,690 |
| Total operating expenses | 24,077,335 | 16,272,931 | 75,958,284 | 50,909,552 |
| LOSS FROM OPERATIONS | (13,800,977) | (9,050,428) | (47,694,588) | (33,597,518) |
| OTHER INCOME (EXPENSE): | ||||
| Interest and other income | 1,164 | 281,896 | 268,643 | 619,103 |
| Interest expense | (3,091,200) | (2,649,404) | (8,875,597) | (6,262,489) |
| Loss on extinguishment of debt | 0 | 0 | 0 | (9,962,495) |
| Gain on transfer of plasma center assets | 0 | 0 | 0 | 11,527,421 |
| Other expense, net | (26,440) | (20,523) | (39,232) | (42,308) |
| Other income expense, net | (3,116,476) | (2,388,031) | (8,646,186) | (4,120,768) |
| NET LOSS | $ (16,917,453) | $ (11,438,459) | $ (56,340,774) | $ (37,718,286) |
| BASIC AND DILUTED LOSS PER COMMON SHARE | $ (0.19) | $ (0.19) | $ (0.68) | $ (0.72) |
| WEIGHTED AVERAGE COMMON SHARES OUTSTANDING: | ||||
| Basic and Diluted | 87,698,258 | 59,317,830 | 82,627,753 | 52,673,190 |
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The aggregate cost of goods produced and sold and services rendered during the reporting period. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of gain (loss) on sale or disposal of other assets. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of the cost of borrowed funds accounted for as interest expense. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of interest income earned from interest bearing assets classified as other. No definition available.
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. No definition available.
|
| X | ||||||||||
- Definition The net result for the period of deducting operating expenses from operating revenues. No definition available.
|
| X | ||||||||||
- Definition The total amount of other operating cost and expense items that are associated with the entity's normal revenue producing operation. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of income (expense) related to nonoperating activities, classified as other. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS). No definition available.
|
| X | ||||||||||
- References No definition available.
|